Cargando…

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

BACKGROUND: Cerebral oedema is associated with significant neurological damage in patients with traumatic brain injury. Bradykinin is an inflammatory mediator that may contribute to cerebral oedema by increasing the permeability of the blood-brain barrier. We evaluated the safety and effectiveness o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shakur, Haleema, Andrews, Peter, Asser, Toomas, Balica, Laura, Boeriu, Cristian, Quintero, Juan Diego Ciro, Dewan, Yashbir, Druwé, Patrick, Fletcher, Olivia, Frost, Chris, Hartzenberg, Bennie, Mantilla, Jorge Mejia, Murillo-Cabezas, Francisco, Pachl, Jan, Ravi, Ramalingam R, Rätsep, Indrek, Sampaio, Cristina, Singh, Manmohan, Svoboda, Petr, Roberts, Ian
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794266/ https://www.ncbi.nlm.nih.gov/pubmed/19958521 http://dx.doi.org/10.1186/1745-6215-10-109

Ejemplares similares

Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
por: Roberts, Ian, et al.
Publicado: (2009)

Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
por: Simmon, Vincent F
Publicado: (2009)

CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial
por: Dewan, Yashbir, et al.
Publicado: (2012)

A nested randomised trial of the effect of tranexamic acid on intracranial haemorrhage and infarction in traumatic brain injury (CRASH-3 trial intracranial bleeding mechanistic study): Statistical analysis plan
por: Mahmood, Abda, et al.
Publicado: (2019)

A nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-Study [CRASH-3 IBMS])
por: Mahmood, Abda, et al.
Publicado: (2017)

Managing clinical trials
por: Farrell, Barbara, et al.
Publicado: (2010)

Aneurysmal subarachnoid haemorrhage: effect of CRHR1 genotype on fatigue and depression
por: Vetkas, Artur, et al.
Publicado: (2020)

Aneurysmal subarachnoid haemorrhage: Effect of CRHR1 genotype on mental health-related quality of life
por: Vetkas, Artur, et al.
Publicado: (2020)

Effect of Bradykinin Postconditioning on Ischemic and Toxic Brain Damage
por: Lalkovičová, Mária, et al.
Publicado: (2015)

Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial
por: Roberts, Ian, et al.
Publicado: (2018)

Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach
por: Williams, Jack, et al.
Publicado: (2020)

Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
por: Mansukhani, Raoul, et al.
Publicado: (2020)

Use of the Oxford Handicap Scale at hospital discharge to predict Glasgow Outcome Scale at 6 months in patients with traumatic brain injury
por: Perel, Pablo, et al.
Publicado: (2008)

Bradykinin/bradykinin 1 receptor promotes brain microvascular endothelial cell permeability and proinflammatory cytokine release by downregulating Wnt3a
por: Huang, Linqiang, et al.
Publicado: (2022)

The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial
por: Shakur, Haleema, et al.
Publicado: (2010)

The effect of natriuretic peptides and bradykinin on development of brain oedema after ischemic stroke
por: Dobrivojević, Marina, et al.
Publicado: (2015)

Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial
por: Li, Bernadette, et al.
Publicado: (2018)

Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis
por: Meng, Xin, et al.
Publicado: (2021)

Electroencephalogram desynchronization in brain trauma patients
por: Rätsep, I, et al.
Publicado: (2008)

A cost-effectiveness and value of information analysis to inform future research of tranexamic acid for older adults experiencing mild traumatic brain injury
por: Williams, Jack, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Administering Tranexamic Acid to Bleeding Trauma Patients Using Evidence from the CRASH-2 Trial
por: Guerriero, Carla, et al.
Publicado: (2011)

Bradykinin, as a Reprogramming Factor, Induces Transdifferentiation of Brain Astrocytes into Neuron-like Cells
por: Lee, Tsong-Hai, et al.
Publicado: (2021)

Bradykinin receptor expression and bradykinin-mediated sensitization of human sensory neurons
por: Yi, Jiwon, et al.
Publicado: (2023)

Prehospital Ground Transport Rapid Sequence Intubation for Trauma and Traumatic Brain Injury Outcomes
por: Fitzgerald, Mark C., et al.
Publicado: (2019)

Neprilysin Inhibitors and Bradykinin
por: Campbell, Duncan J.
Publicado: (2018)

Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP(9α)
por: Mueller, Sylvia, et al.
Publicado: (2005)

The effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trial
por: Shakur, Haleema, et al.
Publicado: (2016)

Tumor-penetrating peptide for systemic targeting of Tenascin-C
por: Lingasamy, Prakash, et al.
Publicado: (2020)

Risk factors for peripartum hysterectomy among women with postpartum haemorrhage: analysis of data from the WOMAN trial
por: Huque, Sumaya, et al.
Publicado: (2018)

Trial management: we need a cadre of high-class triallists to deliver the answers that patients need
por: Beaumont, Danielle, et al.
Publicado: (2019)

The impact of early outcome events on the effect of tranexamic acid in post-partum haemorrhage: an exploratory subgroup analysis of the WOMAN trial
por: Brenner, Amy, et al.
Publicado: (2018)

Outcome measures in clinical trials of treatments for acute severe haemorrhage
por: Brenner, Amy, et al.
Publicado: (2018)

Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials
por: Kolin, David A., et al.
Publicado: (2020)

Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: Statistical analysis plan for the WOMAN-2 trial: an international, randomised, placebo-controlled trial
por: Collier, Tim, et al.
Publicado: (2023)

Bradykinin and the Pathogenesis of Hereditary Angioedema
por: Kaplan, Allen P
Publicado: (2011)

Cardiovascular Activities of of the bradykinin system
por: Sharma, Jagdish N.
Publicado: (2008)

Using a business model approach and marketing techniques for recruitment to clinical trials
por: McDonald, Alison M, et al.
Publicado: (2011)

Economic evaluation of tranexamic acid for the treatment of acute gastrointestinal bleeding: a cost-effectiveness analysis using data from the HALT-IT randomised controlled trial
por: Bazeer, Nuha, et al.
Publicado: (2022)

Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial
por: Ker, Katharine, et al.
Publicado: (2012)

Functional outcome of corpectomy in cervical spondylotic myelopathy
por: Williams, Kanishka E, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_n3knb470806gljgbg9j0av0cra